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In this issue of Blood, Fernandez et al demonstrate that human leukocyte antigen (HLA) DRB1 alleles confer high-affinity binding to asparaginase epitopes, leading to higher frequency of allergic reactions. 1 The authors initially examined HLA data from European ancestry patients enrolled onto St. Jude Children's Research Hospital (n 5 541) and the Children's Oncology Group (n 5 1329) clinical trials and identified a higher incidence of allergic reactions and anti-asparaginase antibodies in patients with HLA-DRB1*07:01 alleles. They then analyzed the structure of the HLA protein to show high-risk amino acids located within the binding pocket (see figure) , possibly affecting the interaction between asparaginase epitopes and the HLA-DRB1 protein.
A relationship between genetic aberrations and adverse drug reactions is not novel, as was demonstrated for 6-mercaptopurine and its metabolizing enzyme, thiopurine S-methyltransferase.
2 Specifically, defects in the thiopurine S-methyltransferase gene lead to decreased inactivation of 6-mercaptopurine and enhanced toxicity, which can cause severe life-threatening myelosuppression. Further, HLA-B alleles were associated with How to treat old MCL patients: one size fits it all? 1 Medical knowledge in hematologic malignancies is based on currently available data, preferably from prospective trials; however, these data are limited by recruitment of fit, predominantly younger patients in most trials. Thus, additional data on a more representative patient population, including elderly patients, are urgently needed.
D
ata from national registries were collected for more than a decade, with 1389 patients with MCL identified. The data confirmed the favorable prognosis of both patients with localized stage I/II treated with curative intent as well as patients with a more indolent presentation who were treated using a watchful-waiting approach. 2 It is reassuring that clinical risk scores and benefits of dose-intensified approaches in younger patients have been confirmed in this large series. 3, 4 However, with a median age of 71 years and two-thirds of patients .65 years, patients in this study were predominantly elderly. In a recent study of an elderly patient population, excellent long-term survival rates were reported using a conventional immunotherapy. 5 Similarly, another large European trial has reported long-term remissions approaching the results achieved with indolent lymphoma. In both of these studies, median age was about 70 years, similar to the current report. However, the patient populations differ significantly, as only fit elderly patients qualified for prospective trials due to restrictive inclusion criteria. Also, in the current survey, treatment approaches varied over a broad range, from autologous stem cell transplantation to chlorambucil only.
